PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Company ReportsExeltis
Exeltis
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Loading
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
DrospirenoneDrospirenone2022-06-292025-2031
—
EstrasorbEstradiol hemihydrate2003-10-092024-2037
Contraception
,
Leiomyoma
,
Breast neoplasms
,
Hot flashes
,
Hypogonadism
,
Menorrhagia
,
Premature menopause
,
Primary ovarian insufficiency
,
Prostatic neoplasms
SlyndDrospirenone2019-05-232025-2031
—
TyblumeEthinyl estradiol, Levonorgestrel2020-03-302023-2039
Contraception,
Breast neoplasms,
Hot flashes,
Hypogonadism,
Menorrhagia,
Premature menopause,
Primary ovarian insufficiency,
Prostatic neoplasms
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Sodium chloride
hemolytic-uremic syndrome
Inm004
hemolytic-uremic syndrome
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use